Document:

EX-10.20

 Exhibit 10.20 
 Prothena Biosciences Inc 
 December 3,
2012 
 Dear Tara: 
 Further to
your Letter of Intent for Neotope Employment (dated September 26, 2012), I am pleased to confirm this offer to join Prothena Biosciences Inc1 (“Prothena” or the “Company”), commencing on the day following the closing date of the demerger
(the “Transaction”) of the Company (and its affiliates) from Elan Corporation, plc – currently expected to occur on or around December 20, 2012. This offer is contingent upon the closing of the Transaction and to the extent the
closing of the Transaction occurs earlier/later than December 20, 2012, your Start Date at Prothena will be adjusted accordingly.2 In the event that the closing of the Transaction does not occur, this offer will terminate and the terms of this offer
letter will not apply. 
 We are confident in your knowledge, expertise and judgment, and believe your performance will meet the high-quality
objectives and standards set by Prothena leadership and management. You will be employed as Head of Corporate/Business Development, reporting to me, although your duties and title may change, based on the Company’s needs and priorities.
This is a full-time, exempt position. 
 Your original date of hire with Elan and its subsidiaries will remain as your original date of hire
within Prothena’s programs relating to employment, compensation and employee benefit plans. 
 Your starting salary will be
$275,000.00 annually, paid twice per month. Your pay is subject to applicable taxes and withholdings. 
 Prothena embraces a
pay-for-performance philosophy. All employees are currently eligible for an annual cash bonus under the terms of the Company’s cash incentive plan (Prothena Biosciences Inc Incentive Compensation Plan). Cash incentive awards are determined by a
number of factors, including industry competitiveness, Prothena’s business strategy, and the degree to which Company, function and/or individual goals are met. The target bonus opportunity for your position is currently 30% of plan year
salaried-earnings. A condition to earning a cash incentive award is that an employee remains employed through the pay date of the award, which will be not later than March 15 in the year following the conclusion of the plan year. The cash bonus
plan is operated at the sole discretion of Prothena, is subject to review on a regular basis and may change from time to time. 
 You will be eligible to receive an equity award of
54,0003 stock options in connection with your
commencement of employment following the Transaction. This award is at the discretion of the Prothena Board of Directors and is subject to its approval, the terms of the Company’s equity incentive plan (Prothena Corporation plc 2012 Long
Term Incentive Plan), and the Company’s standard equity award agreement. The Exercise Price will be set as the average of the closing price of Prothena’s ordinary shares for the first 25 trading days commencing on the first day of trading
on the NASDAQ Global Market listing. The Grant Date will be the 25th trading
day.4 The award will vest 25% after the first year of
active service from the Grant Date, and monthly at a rate of 1/48th of the award thereafter, such that the award will fully vest after a four-year period of continuous employment. 

 

	1 	The legal entity Neotope Biosciences, Inc. was renamed Prothena Biosciences Inc on November 1, 2012 

	2 	Your final day of Elan employment will be deemed the date of the closing of the Transaction; your first date of Prothena employment will be the following day

	3 	This represents slightly more than 0.30% of Prothena’s expected common shares outstanding post Transaction. 

	4 	Assumes approval on Start Date by Prothena’s Board of Directors; should approval occur at a later date, the 25-day period would start on the date of approval.

 Prothena Biosciences Inc 
 On the first day of the month following your Start Date of employment, you will be eligible to participate in Prothena’s comprehensive benefits program, including the company’s health and
welfare and retirement benefit plans. Details about these and other applicable plans will be provided separately, as will further information regarding certain onboarding items and other documents needed before your Start Date (e.g., direct deposit
election, W-4 allowances, Employee Proprietary Information and Invention Assignment Agreement). 
 Your employment is “at will.” This
means that you or Prothena each has the right to terminate the employment relationship at any time, with or without cause. Nothing in this letter should be taken as a guarantee of continued employment or a specific term of employment. Further, all
benefits and compensation provided by the Company are contingent upon your continued employment. 
 To accept our offer, please sign this letter
and return to Kevin Hickey by Tuesday, December 11, 2012. By signing this letter, you acknowledge that it sets out our entire agreement between the parties and supersedes all prior oral and written agreements, understandings, commitments
and practices between the parties, including the Letter of Intent for Neotope Employment dated September 26, 2012. No amendments to this agreement may be made except in writing signed by a duly authorized representative of Prothena.

 We look forward to having you join Prothena. If you have any questions, or would like additional information to help you reach a decision,
please feel free to contact Kevin at (650) 278-1762. 
 Sincerely, 
 /s/ Dale Schenk 
 Dale Schenk 
 President and CEO 
 Prothena Biosciences Inc 

ACCEPTANCE: 
  

					
			
	/s/ Tara Nickerson	 		 	Dec. 14, 2012
	Tara Nickerson	 		 	DateEX-4.1

 Exhibit 4.1 

 

	
	

 INCORPORATED UNDER THE LAWS OF THE STATE OF MARYLAND 

COMMON STOCK 
 PAR VALUE $0.01 PER SHARE 
 CUSIP 848568 30 9

 SEE REVERSE FOR IMPORTANT NOTICE ON TRANSFER RESTRICTIONS AND OTHER INFORMATION 

Spirit Realty Capital, inc. 
 THIS CERTIFIES THAT 
 SPECIMEN 

IS THE OWNER OF 
 FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, PAR VALUE $0.01, OF SPIRIT REALTY CAPITAL, INC. 
 (the “Corporation”) transferable on the books of the Corporation by the holder hereof in person or by its duly authorized attorney, upon surrender of this Certificate properly
endorsed. This Certificate and the shares represented hereby are issued and shall be held subject to all of the provisions of the Charter of the Corporation (this “Charter”) and the Bylaws of the Corporation and any amendments thereto.
This Certificate is not valid unless countersigned and registered by the Transfer Agent and Registrar. 
 Witness
the facsimile signatures of the Corporation’s duly authorized officers. 
 Dated: 

COUNTERSIGNED AND REGISTERED: 
 AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC 
 (BROOKLYN, NY) 
 TRANSFER AGENT PRESIDENT AND
REGISTRAR 
 BY 
 AUTHORIZED SIGNATURE SECRETARY 

 IMPORTANT NOTICE 
 THE CORPORATION WILL FURNISH TO ANY STOCKHOLDER, ON REQUEST AND WITHOUT CHARGE, A FULL STATEMENT OF THE INFORMATION REQUIRED BY SECTION 2-211(B) OF THE CORPORATIONS AND ASSOCIATIONS ARTICLE OF THE
ANNOTATED CODE OF MARYLAND (OR ANY SUCCESSOR STATUTE OR PROVISION). SUCH REQUEST MUST BE MADE TO THE SECRETARY OF THE CORPORATION AT ITS PRINCIPAL OFFICE OR TO THE TRANSFER AGENT. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON BENEFICIAL AND CONSTRUCTIVE OWNERSHIP AND TRANSFER FOR THE PURPOSE OF THE CORPORATION’S MAINTENANCE OF ITS STATUS AS A REAL
ESTATE INVESTMENT TRUST UNDER THE INTERNAL REVENUE CODE OF 1986, AS AMENDED (THE “CODE”). SUBJECT TO CERTAIN FURTHER RESTRICTIONS AND EXCEPT AS EXPRESSLY PROVIDED IN THE CORPORATION’S CHARTER, (I) NO PERSON MAY BENEFICIALLY OR
CONSTRUCTIVELY OWN SHARES OF THE CORPORATION’S COMMON STOCK IN EXCESS OF THE COMMON STOCK OWNERSHIP LIMIT UNLESS SUCH PERSON IS AN EXCEPTED HOLDER (IN WHICH CASE THE EXCEPTED HOLDER LIMIT SHALL BE APPLICABLE); (II) NO PERSON MAY BENEFICIALLY OR
CONSTRUCTIVELY OWN SHARES OF CAPITAL STOCK OF THE CORPORATION IN EXCESS OF THE AGGREGATE STOCK OWNERSHIP LIMIT, UNLESS SUCH PERSON IS AN EXCEPTED HOLDER (IN WHICH CASE THE EXCEPTED HOLDER LIMIT SHALL BE APPLICABLE); (III) NO PERSON MAY BENEFICIALLY
OR CONSTRUCTIVELY OWN CAPITAL STOCK THAT WOULD RESULT IN THE CORPORATION BEING “CLOSELY HELD” UNDER SECTION 856(H) OF THE CODE OR OTHERWISE CAUSE THE CORPORATION TO FAIL TO QUALIFY AS A REIT; AND (IV) NO PERSON MAY TRANSFER SHARES OF
CAPITAL STOCK IF SUCH TRANSFER WOULD RESULT IN THE CAPITAL STOCK OF THE CORPORATION BEING OWNED BY FEWER THAN 100 PERSONS. ANY PERSON WHO BENEFICIALLY OR CONSTRUCTIVELY OWNS OR ATTEMPTS TO BENEFICIALLY OR CONSTRUCTIVELY OWN SHARES OF CAPITAL STOCK
WHICH CAUSES OR WILL CAUSE A PERSON TO BENEFICIALLY OR CONSTRUCTIVELY OWN SHARES OF CAPITAL STOCK IN EXCESS OR IN VIOLATION OF THE ABOVE LIMITATIONS MUST IMMEDIATELY NOTIFY THE CORPORATION. IF ANY OF THE RESTRICTIONS ON TRANSFER OR OWNERSHIP SET
FORTH IN (I) THROUGH (III) ABOVE ARE VIOLATED, THE SHARES OF CAPITAL STOCK REPRESENTED HEREBY WILL BE AUTOMATICALLY TRANSFERRED TO A TRUSTEE OF A TRUST FOR THE BENEFIT OF ONE OR MORE CHARITABLE BENEFICIARIES. IN ADDITION, THE CORPORATION MAY
TAKE OTHER ACTIONS, INCLUDING REDEEMING SHARES UPON THE TERMS AND CONDITIONS SPECIFIED BY THE BOARD OF DIRECTORS IN ITS SOLE AND ABSOLUTE DISCRETION IF THE BOARD OF DIRECTORS DETERMINES THAT OWNERSHIP OR A TRANSFER OR OTHER EVENT MAY VIOLATE THE
RESTRICTIONS DESCRIBED ABOVE. FURTHERMORE, UPON THE OCCURRENCE OF CERTAIN EVENTS, ATTEMPTED TRANSFERS IN VIOLATION OF THE RESTRICTIONS DESCRIBED ABOVE MAY BE VOID AB INITIO. ALL CAPITALIZED TERMS IN THIS LEGEND HAVE THE MEANINGS DEFINED IN THE
CHARTER OF THE CORPORATION, AS THE SAME MAY BE AMENDED FROM TIME TO TIME, A COPY OF WHICH, INCLUDING THE RESTRICTIONS ON TRANSFER AND OWNERSHIP, WILL BE FURNISHED TO EACH HOLDER OF CAPITAL STOCK OF THE CORPORATION ON REQUEST AND WITHOUT CHARGE.
REQUESTS FOR SUCH A COPY MAY BE DIRECTED TO THE SECRETARY OF THE CORPORATION AT ITS PRINCIPAL OFFICE. 
  

													
	 TEN COM
	  	—	  	as tenants in common	  	UNIF GIFT/TRANS MIN ACT–	  	 	 	Custodian    	  	 
	 TEN ENT
	  	—	  	as tenants by the entireties	  		  	(Cust)	 		  	(Minor)
	 JT TEN
	  	—	  	as joint tenants with right of	  		  	under Uniform Gifts/Transfers to Minors Act
		  		  	survivorship and not as tenants	  		  	 
		  		  	in common	  		  		 	(State)	  	

 Additional abbreviations may also be used though not in the above list. 

FOR VALUE RECEIVED,
                                         
                                HEREBY SELL, ASSIGN AND TRANSFER UNTO 

 

					
	 PLEASE INSERT SOCIAL SECURITY OR OTHER

IDENTIFYING NUMBER OF ASSIGNEE
	  		  	
	 		
	 	  		  	

  
  

(Please Print or Typewrite Name and Address, Including Zip Code, of Assignee) 
 ____________________________________________________________________________________________________Shares of the shares represented by the within Certificate, and do hereby irrevocably constitute and
appoint 
 ___________________________________________________________________________________________________Attorney to transfer the said
shares on the books of the within named Corporation with full power of substitution in the premises. 
  

							
	Dated	 	 	 		  	  

		 		 		  	NOTICE: The Signature To This Assignment Must Correspond With The Name As Written Upon The Face Of The Certificate In Every Particular, Without Alteration Or Enlargement Or Any
Change Whatever.

  

			
	SIGNATURE(S) GUARANTEED:	 	  

		 	THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED
SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO S.E.C. RULE 17Ad-15.

 KEEP THIS CERTIFICATE IN A SAFE PLACE. IF IT IS LOST, STOLEN, MUTILATED OR DESTROYED, THE CORPORATION WILL REQUIRE A
BOND OF INDEMNITY AS A CONDITION TO THE ISSUANCE OF A REPLACEMENT CERTIFICATE.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]